Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization.
Duration: April 1, 2014
to
April 1, 2023
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code
Spending: about $1,780,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stephen Northrup HealthPolDirector,Senate HELP Cmte;HealthPolAdv,Sen. Enzi
Stacey Rampy LD, Rep. Eshoo; LA, Sen. Torricelli; LA, Sen. Boxer
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2023
Rampy Northrup LLC terminated an engagement in which they represented Johnson & Johnson Services, Inc. on Sept. 29, 2023.
Original Filing: 301496817.xml
2nd Quarter, 2023
In Q2, Rampy Northrup LLC did no lobbying for Johnson & Johnson Services, Inc. . The report was filed on July 20, 2023.
Original Filing: 301489586.xml
1st Quarter, 2023
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $30,000. The report was filed on April 20, 2023.
Original Filing: 301466345.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301432307.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization;
H.R.6000, Cures 2.0 Act;
H.R.5030/S.2706, DIVERSE Trials Act;
H.R.5585, Advanced Research Project Agency-Health Act;
S.3799, PREVENT Pandemics Act;
H.R.7667, Food and Drug Amendments of 2022;
S.4348, FDASLA Act of 2022;
H.R.2617, Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 19, 2022.
Original Filing: 301409274.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization;
H.R.6000, Cures 2.0 Act;
H.R.5030/S.2706, DIVERSE Trials Act;
FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169);
H.R.5585, Advanced Research Project Agency-Health Act;
S.3799, PREVENT Pandemics Act;
H.R.7667, Food and Drug Amendments of 2022;
S.4348, FDASLA Act of 2022;
H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301391012.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization;
H.R.3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R.6000, Cures 2.0 Act;
H.R.5030/S.2706, DIVERSE Trials Act;
FY2022 Budget Reconciliation (H.R.5376);
H.R.5585, Advanced Research Project Agency-Health Act;
S.3799, PREVENT Pandemics Act;
H.R.7667, Food and Drug Amendments of 2022;
S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 19, 2022.
Original Filing: 301363170.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization;
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R.6000, Cures 2.0 Act;
H.R.5030/S.2706, DIVERSE Trials Act;
FY2022 Budget Reconciliation (H.R.5376);
H.R.5585, Advanced Research Project Agency-Health Act;
S.3799, PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301333450.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R.6000, Cures 2.0 Act;
H.R.5030/S.2706, DIVERSE Trials Act;
FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301309083.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.3, Elijah E. Cummings Lower Drug Costs Now Act;
CURES 2.0 Act discussion draft;
H.R.5030/S.2706, DIVERSE Trials Act;
FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301288580.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2);
CURES 2.0 discussion draft;
H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301264068.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.5663/S.4225, Safeguarding Therapeutics Act (P.L.116-304);
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241183.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.6201, Families First Coronavirus Response Act (P.L.116-127);
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.6800, The Heroes Act;
Implementation of H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139);
H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act;
H.R.5663/S.4225, Safeguarding Therapeutics Act;
H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222106.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs;
Implementation of H.R.6201, Families First Coronavirus Response Act (P.L.116-127);
Implementation of H.R.748, CARES Act (P.L.116-136);
H.R.6800, The Heroes Act;
Implementation of H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139);
H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act;
H.R.5663/S.4225, Safeguarding Therapeutics Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301197238.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health;
S.1895, Lower Health Care Costs Act of 2019;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123);
H.R.6201, Families First Coronavirus Response Act (P.L.116-127);
H.R.748, CARES Act (P.L.116-136);
H.R.6800, The Heroes Act;
H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019;
S.2543, Prescription Drug Pricing Reduction Act of 2019;
H.R.19, Lower Costs, More Cures Act of 2019;
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301176954.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response;
S.1895, Lower Health Care Costs Act of 2019;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123);
H.R.6201, Families First Coronavirus Response Act (P.L.116-127);
H.R.748, CARES Act (P.L.116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019;
S.2543, Prescription Drug Pricing Reduction Act of 2019;
H.R.19, Lower Costs, More Cures Act of 2019;
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301125180.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to medical device tax; H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301074954.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2019.
Original Filing: 301053283.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of 21st Century Cures Act (P.L.114-255).
H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 including provisions related to the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031898.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of 21st Century Cures Act (P.L.114-255).
H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 including provisions related to the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 20, 2019.
Original Filing: 301011344.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
S.1113, Personal Care Products Safety Act.
S.2003, FDA Cosmetic Safety and Modernization Act.
S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act.
H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018.
H.R.6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 21, 2018.
Original Filing: 300993670.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
S.1113, Personal Care Products Safety Act.
S.2003, FDA Cosmetic Safety and Modernization Act.
S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act.
H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018.
S.2680, Opioid Crisis Response Act of 2018.
H.R.6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 18, 2018.
Original Filing: 300968932.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
S.1113, Personal Care Products Safety Act.
S.2003, FDA Cosmetic Safety and Modernization Act.
OTC Monograph Reform.
S.2680, Opioid Crisis Response Act of 2018.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950581.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
S.1113, Personal Care Products Safety Act.
S.2003, FDA Cosmetic Safety and Modernization Act.
OTC Monograph Reform.
H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123)/H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300930873.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
S.1113, Personal Care Products Safety Act.
S.2003, FDA Cosmetic Safety and Modernization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1, Tax Cuts and Jobs Act (P.L.115-97); issues related to repatriation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300913241.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
FDA User Fee legislation; H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52).
S.1113, Personal Care Products Safety Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300892198.xml
Lobbying Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Implementation of the 21st Century Cures Act (P.L.114-255).
FDA User Fee legislation; H.R.2430/S.934, FDA Reauthorization Act of 2017.
S.1113, Personal Care Products Safety Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 18, 2017.
Original Filing: 300867219.xml
Lobbying Issues
Implementation of the 21st Century Cures Act (P.L.114-255).
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
FDA User Fee legislation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 19, 2017.
Original Filing: 300852157.xml
Lobbying Issues
H.R.34, 21st Century Cures Act (P.L.114-255).
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
H.R.3381/S.1883, Childhood Cancer STAR Act.
S.1014, Personal Care Products Safety Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 19, 2016.
Original Filing: 300831517.xml
Lobbying Issues
H.R.6, 21st Century Cures Act.
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
H.R.3381/S.1883, Childhood Cancer STAR Act.
S.1014, Personal Care Products Safety Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300813579.xml
Lobbying Issues
H.R.6, 21st Century Cures Act.
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
H.R.3381/S.1883, Childhood Cancer STAR Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300797999.xml
Lobbying Issues
H.R.6, 21st Century Cures Act.
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300778302.xml
Lobbying Issues
H.R.6, 21st Century Cures Act.
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300760032.xml
Lobbying Issues
H.R.6, 21st Century Cures Act.
S.1767, Combination Product Regulatory Fairness Act of 2015.
H.R.2433, To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 18, 2015.
Original Filing: 300739721.xml
Lobbying Issues
P.L.114-10, Medicare Access and CHIP Reauthorization Act of 2015.
H.R.6, 21st Century Cures Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718016.xml
Lobbying Issues
H.R.2, Medicare Access and CHIP Reauthorization Act of 2015.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 16, 2015.
Original Filing: 300697300.xml
Lobbying Issues
H.R.4250/S.2141, Sunscreen Innovation Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
H.R.83, Consolidated and Further Continuing Appropriations Act, 2015; issues related to Ebola funding.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2014.
Original Filing: 300682878.xml
Lobbying Issues
H.R.4250/S.2141, Sunscreen Innovation Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Rampy Northrup LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300660718.xml
Lobbying Issues
H.R.4250, Sunscreen Innovation Act.
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
Rampy Northrup LLC filed a lobbying registration on May 4, 2014 to represent Johnson & Johnson Services, Inc., effective April 1, 2014.
Original Filing: 300650929.xml
Issue(s) they said they’d lobby about: Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...